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Biomarkers of collagen turnover are related
to annual change in FEV1 in patients with
chronic obstructive pulmonary disease
within the ECLIPSE study
Diana J. Leeming1*, Inger Byrjalsen1, Jannie M. B. Sand1,2, Asger R. Bihlet1, Peter Lange2, The Evaluation of COPD
Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators, Ruth Thal-Singer3*, Bruce E. Miller3*,
Morten A. Karsdal1 and Jørgen Vestbo4*
Abstract
Background: Change in forced expiratory volume in one second (FEV1) is important for defining severity of chronic
obstructive pulmonary disease (COPD). Serological neoepitope markers of collagen turnover may predict rate of
change in FEV1.
Methods: One thousand COPD subjects from the observational, multicentre, three-year ECLIPSE (Evaluation of COPD
Longitudinally to Identify Predictive Surrogate Endpoints) study (NCT00292552, trial registration in February 2006) were
included. Matrix metalloproteinase (MMP)-generated fragments of collagen type I, and type VI (C1M and C6M) were
assessed in month six serum samples. A random-coefficient model with both a random intercept and a random slope
was used to test the ability of the markers to predict post-dose bronchodilator FEV1 (PD-FEV1) change over two years
adjusting for sex, age, BMI, smoking, bronchodilator reversibility, prior exacerbations, emphysema and chronic
bronchitis status at baseline.
Results: Annual change of PD-FEV1 was estimated from a linear model for the two-year study period. Serum C1M and
C6M were independent predictors of lung function change (p = 0.007/0.005). Smoking, bronchodilator reversibility,
plasma hsCRP and emphysema were also significant predictors. The effect estimate between annual change in PD-FEV1
per one standard deviation (1SD) increase of C1M and C6M was +10.4 mL/yr. and +8.6 mL/yr. C1M, and C6M, had a
significant association with baseline FEV1.
Conclusion: We demonstrated that markers of tissue turnover were significantly associated with lung function change.
These markers may function as prognostic biomarkers and possibly as efficacy biomarkers in clinical trials focusing on
lung function change in COPD.
Trial registration: NCT00292552, Retrospectively registered, trial registration in February 2006.
Keywords: COPD, Lung function change, Prognosis, Serological marker, Extracellular matrix
* Correspondence: djl@nordicbio.com; djl@nordicbioscience.com; Ruth.M.Tal-
Singer@gsk.com; bruce.e.miller@gsk.com; Jorgen.Vestbo@manchester.ac.uk
1Nordic Bioscience, Fibrosis Biology and Biomarkers, Herlev Hovedgade 207,
DK-2730 Herlev, Denmark
3GlaxoSmithKline Research and Development, King of Prussia, PA, United States
4Centre for Respiratory Medicine and Allergy, Manchester Academic Science
Centre, The University of Manchester and University Hospital South
Manchester NHS Foundation Trust, Manchester, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Leeming et al. BMC Pulmonary Medicine  (2017) 17:164 
DOI 10.1186/s12890-017-0505-4
Background
Chronic obstructive pulmonary disease (COPD) is a
leading cause of morbidity and mortality worldwide and
is a disease leading to narrowing of the small airways,
airway fibrosis and chronic changes in the lung paren-
chyma [1] mainly due to cigarette- or biomass smoke ex-
posure [2]. Phenotyping of patients is generally based on
a combination of clinical and morphological features
such as frequency of exacerbations, lung function, pres-
ence or absence of emphysema and chronic bronchitis,
and presence of asthmatic features [3, 4]. Therapies af-
fecting such parameters in COPD are limited [5].
In COPD, the airway composition and structure is
changed compared to the healthy state, due to small air-
way inflammation resulting in epithelial damage and
subsequent airway fibrosis with increased deposition and
remodelling of extracellular matrix (ECM) proteins in
the basement membrane and interstitial matrix [6–8] of
the lung. Activated lung fibroblasts deposit ECM pro-
teins, such as collagens type I and III, fibronectin, lam-
inin [7, 9–11], biglycan, decorin and perlecan [12], all
alleged of having severe effects on the lung integrity.
These proteins are believed to be elevated and remod-
elled during chronic inflammation in the small airways.
Furthermore, pathological proteases such as elastase
[13], and matrix metalloproteinase (MMP)-1, −2, −7, −9
and −12 [14] have been reported to be over-expressed in
COPD affected tissue [15]. The most abundant collagen
in the interstitial matrix of the lung is the fibril-forming
type I collagen [16] which is mainly found located along-
side with type III collagen, the second most abundant
collagen type. Together they provide the structural
framework of the alveolar wall, pulmonary blood vessels,
visceral pleura and the connective tissue sheaths that
surround the tracheobronchial tree [17, 18]. Type VI col-
lagen is another important member of the collagens of
the interstitial matrix, which main function is to connect
cells to territorial matrix [19, 20]. Recently, it was shown
that circulating neoepitope markers of ECM were related
to clinical outcomes in patients with idiopathic pulmon-
ary fibrosis (IPF) [21]. In IPF, serum markers of MMP-
generated fragments of type I, III, VI collagen, biglycan
and CRP were able to identify patients with fast progres-
sion and high risk of mortality. Generally, markers of
ECM remodellings including C1M and C6M have been
shown to relate to disease activity in the osteoporosis,
COPD and pagets disease, rheumatoid arthritis (RA),
hepatitis C, hepatitis B [22–31] C6M and C1M has been
shown to be elevated in COPD compared to healthy in-
dividuals; C6M is upregulated during AECOPD, however
not related to smoking status or pack years [32–35]. In
the present work, we aimed to investigate the ability of
novel serological ECM related neoepitope markers to
predict rate of change of forced expiratory volume in
one second (FEV1) in COPD patients within the
ECLIPSE study [36]. The markers utilized are highly spe-
cific for the detection of MMP-mediated fragments of
type I (C1M [37]) or type VI collagen (C6M [19]). The
hypothesis was that some of these ECM markers, which
are markers of pulmonary fibrosis in patient with idio-
pathic pulmonary fibrosis (IPF) [21], were able to predict
lung function change in patients with pulmonary struc-
tural changes due to COPD. We speculated that these
markers may be valid as an aid in the selection of pa-
tients in most need of treatment, and patients for clinical
trials focusing on progression of COPD.
Methods
Study design
The present analysis was performed in the three-year
ECLIPSE observational study (ClinicalTrials.gov number,
NCT00292552, trial registration in February 2006) de-
scribed previously [36, 38]. The full ECLIPSE study
included 2164 patients with COPD. Briefly, patients in-
cluded were between 40 and 75 years at baseline, had a
history of ten or more pack-years of smoking, a post-dose
bronchodilator FEV1 less than 80% of the predicted value
and a post-dose bronchodilator ratio of FEV1 to forced
vital capacity (FVC) of 0.7 or less. The Global initiative for
Obstructive Lung Disease (GOLD) spirometry stages in-
cluded were II-IV. Respiratory symptoms, smoking his-
tory, occupational exposure, and coexisting medical
conditions were documented at study entry with the use
of a modified version of the American Thoracic Society–
Division of Lung Disease (ATS-DLD) questionnaire. The
study was conducted in accordance with the Declaration
of Helsinki and good clinical practice guidelines, and was
approved by all local and participating centres’ ethics and
review boards reference number SCO104960 (ECLIPSE)
RM 2005/00273/05 (Additional file 1). All patients pro-
vided their informed written consent. A list of the partic-
pating centers is seen in Additional file 1. Each patient
underwent spirometry before and 15 min after inhaling
400 μg of salbutamol (GlaxoSmithKline). Computed
tomographic (CT) scanning of the chest was performed at
baseline to evaluate the severity and distribution of em-
physema. Quantitative assessment of lung volumes and
estimation of the percentage of lung CT voxels below a
threshold of −950 Hounsfield units and percent low areas
of attenuation (%LAA) was performed using Pulmonary
Workstation software, version 2.0 (VIDA Diagnostics).
Significant amount of emphysema was defined as having
more than 10%LAA. Whole blood was collected by
venipuncture into vacutainer tubes. Serum was prepared
by allowing the blood to clot for 30 min at room tempera-
ture followed by centrifugation at 1500 g for 10–15 min.
Plasma was obtained by centrifugation of vacutainer tubes
at 2000 g for 10–15 min.
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Definition of subpopulation
A subpopulation of 1000 patients was selected from the
ECLIPSE cohort for the purpose of evaluating the ability
of two serum markers of ECM remodeling to predict the
longitudinal change in FEV1 within the study compared
to existing biomarkers assessed within the study. The
500 most rapid post-dose bronchodilator FEV1 (PD-
FEV1) decliners and the 500 slowest PD-FEV1 decliners
were selected for the biomarker assessments. The linear
PD-FEV1 decline was defined as the change in PD-FEV1
from year 1 (Y1) to year 3 (Y3). Baseline to month 6
(M6) PD-FEV1 data were excluded in the present ana-
lysis since the biochemical markers included in the
present study analysis were assessed in serological sam-
ples at different time points: baseline (BL), M6 or Y1. A
schematic overview of the data used is seen in Fig. 1.
This way only PD-FEV1 data obtained post blood sam-
pling were used in the analysis.
Quantification of biochemical markers in the
subpopulation
Serum samples from the M6 visit that had been stored
at −80 °C until used for analysis. Serum levels of a MMP
derived collagen type I fragment (C1M) [37] and a MMP
derived collagen type VI fragment (C6M) [19] were
assessed using competitive enzyme linked immunosorb-
ent assays (ELISAs) (Nordic Bioscience, Herlev, DK) in
the subpopulation of 1000 patients. Technical data on
robustness, specificity and analyte stability are published
for C1M and C6M [37, 19]. Biomarkers were assessed in
a blinded manner according to the manufacturer and all
samples were measured within the detection range.
EDTA plasma levels of CC-16 at BL, hsCRP and fibrino-
gen at Y1 had prior to this study been assessed in the
total ECLIPSE cohort [39]. Thus data of CC-16, hsCRP
and fibrinogen from the ECLIPSE database were used
for analysis.
Statistical analysis
Demographic characteristics have been summarized as
mean with standard deviation (SD) or number of sub-
jects with percentage as applicable. The change in FEV1
over time was estimated from five FEV1 measurements
performed through Y1 to Y3 in the study using a linear
regression model. Negative PD-FEV1 refers to a loss of
FEV1 and positive PD-FEV1 refers to a retaining of PD-
FEV1. A saddle test was performed (proc modeclus) on
all FEV1 change data using a radius of the sphere of sup-
port for uniform-kernel density estimation and the
neighborhood for clustering of R = 10 or R = 20. The as-
sociation of PD-FEV1 and PD-FEV1 in percent of
predicted value (PD-FEV1%) was calculated using a
random-coefficient model with both a random intercept
and a random slope including the co-variates gender,
age, BMI, current smoking status, bronchodilator revers-
ibility, number of prior acute exacerbations, emphysema,
chronic bronchitis status, and number of pack-years at
baseline. A multimarker random-coefficient model in-
cluding C1M, C6M, fibrinogen, and hsCRP in one model
or using stepwise exclusion tested for association to the
linear change of PD-FEV1 was performed. Furthermore,
the association to the linear change of PD-FEV1 was cal-
culated for the total population; in patients stratified
according to GOLD stages B, C and D; and in patients
defined as slow or rapid decliners using a cut-off value
of FEV1 of 40 mL/yr. Levels of C1M, C6M and hsCRP in
patients with or without significant emphysema (%LAA <
10) were tested using a Mann-Whitney unpaired t-test.
The SAS software package (release 9.3; SAS Institute Inc.,
Cary, NC, USA) was used for the statistical calculations.
Funding source
The study was sponsored by GlaxoSmithKline; the Danish
Agency for Science, Technology and Innovation; and the
Danish Research Foundation. Two representatives of
GlaxoSmithKline and one academic, together repre-
senting the ECLIPSE study investigators, two represen-
tatives of Nordic Bioscience developed the present
study design and concept. All approved the plan for the
current analyses, had full access to the data, and were
responsible for the decision to publish. The study spon-
sor did not place any restrictions with regard to state-
ments made in the final paper.
Results
The demographic description of the patient population
is presented in Table 1. The mean annual rates of change
in PD-FEV1 and PD-FEV1% in all patients from year 1 to
year 3 were −43 ± 120 mL and −1.5 ± 4.2%, respectively.
The mean annual rates of change were −132 ± 91 mL
Fig. 1 Histogram showing the distribution of annual FEV1 change in the presented subpopulation of ECLIPSE
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and −4.7 ± 3% for PD-FEV1 and PD-FEV1% in the 500
most rapid decliners and +44 ± 95 mL and +1.6 ± 3% in
the slowest decliners. The distribution of estimated FEV1
change (Fig. 2) showed that most patients lost between
−20 and −200 mL/yr. (60%) or gained 20–160 mL/yr.
(30%) in FEV1 in the two-year period. A saddle test of the
estimated FEV1 change distribution did not indicate that
this parameter followed a bi-phasic distribution. Patients
in the population did genereally have a stable annual rate
of change in FEV1. C1M, C6M and hsCRP were not sig-
nificantly elevated in patients with significant emphysema
(%LAA> 10) compared to those without.
Association between clinical patient characteristics or
single biomarkers and baseline FEV1
There was a statistical significant association between a
range of patient characteristics or biomarkers and base-
line PD-FEV1 (Table 2). Age, BMI, sex, emphysema,
bronchodilator reversibility and no prior exacerbation
showed the most pronounced association (p < 0.0001) in
the total population. An overview of the association for
significant parameters is seen in Fig. 3, showing that
both patient characteristics and biomarkers were able to
describe baseline FEV1 difference. The association of a
1SD change in a biomarker was calculated for each
marker in the subpopulation for PD-FEV1 showing
associations between −53.3 to 38.1 mL (Table 2). Plasma
fibrinogen and hsCRP had the largest association (−53.3/
−53.3 mL, p = 0.0002/0.0003), and serum C1M and C6M
also showed significant association (−45.2 mL, p = 0.002;
−46.5 mL, p = 0.0011) to baseline FEV1.
Association between clinical patient characteristics or
single biomarkers and annual FEV1 change
The effect estimate of a 1SD change in a biomarkers was
calculated for each marker in the total population for the
PD-FEV1 and PD-FEV1% linear change from Y1 to Y3
(Table 2). An overview of the association for significant
parameters is seen in Fig. 3, generally showing that patient
characteristics and biomarkers were able to describe an-
nual change in FEV1 with patient characteristics providing
negative associations and serological markers providing
positive associations. Serum C1M and C6M at 6 months
were independent predictors of lung function change. A
1SD increase in C1M accounted for a decreased rate of
decline of lung function of 10.4 mL/yr. (p = 0.007) in PD-
FEV1. For C6M, a 1SD increase accounted for a a de-
creased rate of annual decline in lung function of 8.6 mL/
yr. (p = 0.03) in PD-FEV1. The rate of change in PD-
FEV1% for C1M was +0.37% (p = 0.005) and for C6M
+0.29% (p = 0.03). The association between C1M and
C6M and PD-FEV1 and PD-FEV1% change was not af-
fected by baseline age, sex, GOLD stage, smoking status,
emphysema, bronchodilator reversibility, and number of
previous exacerbations. Y1 plasma hsCRP accounted for a
rate of change in PD-FEV1 of 8.2 mL (p = 0.04) and 0.30%
for PD-FEV1% (p = 0.03). Smoking status, bronchodilator
reversibility, and emphysema were also confirmed as pre-
dictors. Fibrinogen and CC-16 were not able to predict
rate of Y1 to Y3 annual decline for PD-FEV1 nor PD-
FEV1% in this subpopulation of the ECLIPSE study. The
estimated annual loss in FEV1 using the multimarker
random-coefficient model for C1M, C6M and hsCRP is
shown in Fig. 4. Here the 25th- and the 75th percentile
groups are plotted showing the estimated loss in these
two groups. For C1M, the annual loss of FEV1 was higher
in patients below 46.3 ng/mL (25th percentile group) ver-
sus in patients below 105.5 ng/mL (75th percentile group).
For C6M and hsCRP, the 25th percentile was 11.7- or
1.5 ng/mL, respectively and the 75th percentile 22.5- or
7.45 ng/mL, respectively. There was no significant associa-
tions to PD-FEV1 change within different GOLD stages,
or in patients either being slow- or rapid decliners. A mul-
timarker model including C1M, C6M, fibrinogen and
hsCRP did not increase the association to linear change in
PD-FEV1 compared to the use of single markers.
Discussion
To the best of our knowledge, the present study is the
first of its kind to evaluate the ability of novel serological
Table 1 Population demographics at baseline
Variable N Mean SD SEM
Age (yr) 1000 63.1 7.21 0.2
BMI 1000 26.9 5.9 0.2
Gender (F/M) 363/637 – – –
GOLD stage II(494), III(406), IV(100) – – –
PD-FEV1% 998 50.6 15.2 0.5
%LAA 887 16.3 11.3 0.4
F Female, M Male, PD-FEV1% Percent predicted normal post dose forced
expiratory volume in 1 s, %LAA Percent low areas of attenuation below −950
Hounsfield units, BMI Body mass index
Fig. 2 Schematic overview of data used from the ECLIPSE study for
analysis in the present study. M6 =Month 6 time point
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ECM neoepitope markers, reflecting collagen type I and
VI degradation, to predict the rate of change in lung
function in patients with COPD. We demonstrated that
serum C1M and C6M were independent predictors of
lung function change in COPD patients over a two year
period follow up. Furthermore, a significant correlation
at baseline to FEV1 by several markers and patient char-
acteristic was observed within the study.
The average annual rate of change in lung function
was evaluated in the ECLIPSE study reporting a FEV1
decline of 33 ml per year, including patients that de-
clined, were stable or improved in FEV1 [36]. Several
clinical trials have shown that FEV1 decline was higher
in mild COPD compared to more severe disease [40–43].
Such observations imply that COPD encloses a variety of
patients with diverse FEV1 trajectories [44]. Thus, it has
become a challenge to stratify patients into phenotypes
such as slow and rapid FEV1 decliners. Better patient
stratification and phenotyping by disease activity bio-
markers would provide a highly valued tool for patient
handling in general practice and in clinical trials to enrich
the patient population [45].
Non-serological markers such as the "Body-mass
index, airflow Obstruction, Dyspnoea, and Exercise"
index (BODE), walking tests, exacerbation rate and dys-
pnoea score are known to be related to disease progres-
sion defined by loss of FEV1 and mortality in patients
with COPD [36, 39]. However, there is a medical need
for serological markers of progressive COPD and selec-
tion of patient phenotypes at baseline [46]. It was previ-
ously shown in the ECLIPSE (Evaluation of COPD
Longitudinally to Identify Predictive Surrogate End-
points) study [36] that patient characteristics, but not
most serological biomarkers, were associated to change
in lung function over the three-year period of the study.
The analysis of biomarkers included baseline assessed
Table 2 Association between patients’ characteristics and biomarkers on baseline Forced Expiratory Volume in 1 Second (FEV1)
assessed in millilitres (mL) and annual rate of change in FEV1. Data are shown as mean ± standard error (SE). Data are generated
from a random-coefficient model. The p-values are not corrected for multiple testing
Marker Associationa with
baseline FEV1
P value Associationa with annual
rate of change in FEV1
P value
mL mL/yr
Serological biomarkers
BL CC-16 38.1 ± 15.2 0.012 −3.0 ± 4.0 0.50
BL SP-D 7.6 ± 14.4 0.60 −2.9 ± 3.8 0.50
BL WBC −24.0 ± 14 0.09 −2.8 ± 3.8 0.50
MO6 C1M −45.2 ± 14.4 0.002 10.4 ± 3.9 0.007
MO6 C6M −46.5 ± 14.2 0.0011 8.6 ± 3.8 0.03
Y1 hsCRP −53.3 ± 14.7 0.0003 8.2 ± 4.0 0.04
Y1 Fibrinogen −53.3 ± 14.3 0.0002 6.8 ± 3.9 0.08
Patients characteristics at baseline
Age (per yr) −13.1 ± 2.1 < 0.0001 0.9 ± 0.6 0.10
SEX (female vs male) −358 ± 30.9 < 0.0001 6.8 ± 8.2 0.41
BMI (kg/m2) 10.7 ± 2.7 < 0.0001 0.2 ± 0.7 0.79
# prior AECOPD
1 vs 0 −172 ± 35.0 < 0.0001 2.8 ± 9.6 0.77
2 vs 0 −151 ± 42.8 0.0004 18.9 ± 11.8 0.11
≥ 3 vs 0 −323 ± 42.2 < 0.0001 13.9 ± 13.8 0.31
AECOPD FU Na Na −1.8 ± 1.9 0.35
Current smoker (yes vs no) −19.4 ± 32.1 0.55 −30.7 ± 8.5 0.0003
Bronchodilator reversibility (yes vs. no) 241 ± 34.3 < 0.0001 −22.8 ± 9.1 0.012
Significant emphysema (yes vs. no) −347 ± 31.6 < 0.0001 −27.9 ± 8.4 0.001
Chronic bronchitis (yes vs no) −35.4 ± 31.1 0.26 −9.7 ± 8.2 0.24
#Pack years −0.8 ± 0.6 0.17 0.1 ± 0.2 0.68
CC-16 Club-cell secretory protein-16, SP-D Surfactant protein-D, WBC white blood cell count, C1M MMP derived collagen type I fragment, C6M MMP derived collagen
type VI fragment, hsCRP high sensitive C-reactive protein, BMI Body mass index, AECOPD Acute exacerbations in COPD, FU Follow up, aThe association are calculated as
per increase in 1SD in each biomarker or as indicated for each patient characteristics. na: non applicable
all p values below <0.05 should be bold and italic
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fibrinogen, interleukin-6, interleukin-8, TNF-a, high sen-
sitive C-reactive protein (hsCRP), Club Cell protein-16
(CC-16) and surfactant protein D in a subset of 1793 pa-
tients. Only CC-16 was significantly associated with lung
function change. Increase of one standard deviation of
CC-16 was equal to the protection of 4 ml/yr. (p = 0.04) in
lung function change. hsCRP was only borderline signifi-
cant (p = 0.07), but indicated that increased levels were as-
sociated with a lower rate of lung function decline.
Most serological markers evaluated in stable COPD,
have shown limited value in relation to the pathology in
COPD including sputum neutrophils, circulating white
blood cells (WBC), and protein biomarkers [47]. Krebs
von den Lungen-6 (KL-6), CC-16, surfactant protein-A
(SP-A) and surfactant protein-D (SP-D) are discussed as
serological markers of pulmonary diseases [48–51]. They
have, however, not been convincingly demonstrated to
be of value for patient phenotyping in COPD [48–51].
Desmosine and isodesmosine, two molecules involved in
elastin cross-linking [48], have shown some value [52],
but have not been fully validated for use in COPD. A
marker of blood clotting, fibrinogen, was recently ap-
proved by the Food and Drug Administration (FDA) as a
drug development tool for the use of patient enrichment
in clinical intervention trials [53]. Fibrinogen appears to
be related to COPD exacerbations and mortality and
used as an aid in selection of patients that are most
likely to progress to a clinical outcome that may be used
as a hard endpoint [53].
At present, it has not yet been investigated whether
pulmonary structural changes in the lung ECM in
COPD is interrelated to rate of change in lung function.
In a small number of patients with mild COPD, it has
been shown that C1M and C6M were elevated when
Fig. 4 Estimate of annual loss in FEV1 having a serum biomarker concentration at the level of the 25th percentile (dashed line) and 75th percentile
(full line). C1M: 25 percentile 46.3 ng/mL; 75 percentile: 105.5 ng/mL; C6M: 25 percentile 11.7 ng/mL; 75 percentile: 22.5 ng/mL, hsCRP: 25 percentile
1.50 ng/mL; 75 percentile: 7.45 ng/mL. Subject characteristics: Male, 63 years of age, BMI 26.9 kg/m2, former smoker with a history of 43 pack-years of
smoking, 1 exacerbation in the previous 12 months, no exacerbations during follow-up, bronchodilator irreversible, and absence of emphysema and
chronic bronchitis
Fig. 3 Forest plot of associated effects of serological markers (blue) or patient characteristics (red) to describe (a) baseline FEV1 or (b) predict
annual change in FEV1. The number of mL or change in mL/yr. are based on one standard deviation change for serological biomarkers, yes versus no
for emphysema, bronchodilator reversibility (bron rev), emphysema, current smoker; per year for age; Female versus male for sex; or kg/m2 for BMI.
Number of prior exacerbations (#prior AECOPD) shown here is one versus zero. Data are shown as mean ± standard error range
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compared to healthy controls [54]. Furthermore, import-
ant data have been presented showing that these ECM
neoepitope markers are related to exacerbations [32]
and mortality in COPD [55]. A range of serological bio-
markers have previously been evaluated in the full
ECLIPSE study as predictors of annual rate of change in
FEV1, yet only CC-16 was associated with a decreased
rate of annual decline in lung function with a modest ef-
fect estimate of +4 ± 2 mL/yr. FEV1 per 1 SD change in
plasma CC-16 [36, 56]. In the present study, serum
C1M, C6M and plasma hsCRP were significantly related
to a decreased rate of annual decline in lung function
ranging from +8.2 to +10.4 mL/yr. FEV1 per 1SD change
in each marker during a two year follow up, which was
superior to the association observed for CC-16 [36]. In
the subpopulation analysed in the present work, CC-16
was not significantly related to the rate of lung function
change. It was notable that increasing levels of all the
significant related markers including CC-16 in the full
ECLIPSE study [36] were related to a lower rate of lung
function decline which may indicate that patients with
impaired tissue repair, thus low biomarker levels, pro-
gress the fastest in relation to lung function decline. This
is however speculative at present. The data did not
change when patients were stratified according to GOLD
stage C-D or being slow- or rapid lung function de-
cliners. These data were nevertheless unexpected since
we intuitively regard elevated levels of ECM remodelling
and CRP as being related to poor outcome in patients.
In the literature it has been presented that serum hsCRP
was prognostic of mortality in stable COPD [57, 58] and
that persistent systemic inflammation, here among
others plasma CRP, is associated with poor clinical out-
come in the ECLIPSE cohort [59]. Nevertheless, persist-
ent inflammation was not related to the prevalence of
chronic bronchitis, degree of emphysema, bronchodila-
tor reponse and rate of FEV1 decline in the population
investigated [59]. Finally, WBC, C1M, C6M, hsCRP and
Fibrinogen were associated with a lower baseline FEV1
indicating that severe patients according to lung func-
tion have higher biomarker levels, correlating to the data
published on death outcome [55], as previously men-
tioned. Lange et al. [60] has published how the effect of
small lungs from early age has an effect on FEV1, thus
an effect on diagnosis of COPD, and potentially COPD
phenotypes, and FEV1 change. The ability of predicting
annual rate of change in FEV1 may be different in mild
COPD vs moderate to severe but also depend on base-
line FEV1.
In a small study of COPD patients, Ferrari et al. in-
dicated that plasma hsCRP was not related to mortality
[61], thus data are to some extent contradictory. In-
consistently to the data in the present publication,
Shabann et al. revealed that the highest tertile of serum
CRP levels was associated with greater decline in annual
FEV1 in COPD patients [62], which was not the conclu-
sion of the present work. The discrepancy between the
two studies may relate to the large differences in age,
BMI and FEV1 at study entry. The COPD patients inves-
tigated by Shaaban et al. [62] were younger (mean
36.6 yr), more lean (BMI = 22.6) and had a higher
FEV1% (105%), however had similar rate of annual de-
cline in lung function (33 vs 29 ml). Our findings indi-
cate that various patohology linked pathways in COPD
have a distinct effect on the ECM remodelling thus
levels of ECM neo-epitopes. Finally, in the ECLIPSE
study analysis, we have observed that C1M, C6M and
hsCRP are elevated in patients that died within the study
period compared to those who did not {Sand, 2016 4514
/id, which indicates that high levels of such markers are
related to a poor outcome.
In the present study, there was no relation between
the structure related markers C1M and C6M or CRP
with having significant emphysema or not. This may be
explained by the fact that the emphysema defined
groups are still very heterogeneous and have different
ECM remodelling profiles. It appears that assessment of
MMP degraded collagen type I or type VI and total CRP
are not the correct markers to evaluate emphysema in a
broad population.
The stability of C1M and C6M has in a large cohort of
patients with IPF been shown over a six month time
period [21]. Here it was seen that levels were stable over
time and that patients within the high level or low level
group at baseline stayed within this group over time.
Nevertheless, it was seen that a relative small increase of
C1M and C6M over time in individual IPF patients were
related to loss of FVC or death {Jenkins, 2015 4101 /id}.
These data, eventhough being in IPF, which is a fibro-
genesis related disease, are contradictory to the present
findings in COPD.
We confirmed in this subpopulation that smoking sta-
tus, bronchodilator reversibility, and emphysema were
significantly related to the annual rate of FEV1-decline
ranging between −30.7-27.9 mL/yr. A pronounced and
significant association by both serological markers and
patient characteristics was seen on baseline FEV1. Serum
C1M and C6M, plasma CC-16, hsCRP, and fibrinogen,
age, sex, BMI, prior exacerbations, bronchodilator
reversibility and emphysema had a significant association
with baseline lung capacity. This highlights the import-
ance of these markers and characteristics in the descrip-
tion of COPD traits and potentially their role in patient
stratification. The use of a single marker reflecting few
pathophysiological traits may not be sufficient whereas a
panel of markers most likely may be required for
optimal prognosis assessment and evaluation of efficacy
of intervention of upcoming drugs. However, neither
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C1M nor C6M did in the multimarker model increase
the association with annual change.
Limitations
In general, the rate of decline in FEV1 observed within
the ECLIPSE study was small and highly variable [36]
providing a small window of progression during the two
year period. Furthermore, FEV1 measurements are gen-
erally recognized as being highly variable. In the present
study, the two extreme groups in FEV1 change were se-
lected for analysis thus leaving out the patients with
FEV1 changes in-between; this may have added to lower-
ing data noise observed in real world COPD studies.
Generally, the analysis of serological biochemical
markers using the ELISA technique often has limitations
such as background noise from the normal level of tissue
remodelling and variation inherited into the method.
Here the signal-to-noise ratio may be improved by in-
corporation of disease-related post-translational modifi-
cations such as protease cleavage into the specificity
criteria of a given assay [63].
In perspective, novel protein fingerprint fibrosis
markers as evaluated in the present study may provide a
new clinical opportunity for improved evaluation of the
involvement of small airways fibrosis activity in COPD.
This may add to phenotype stratification and selection
of patients for clinical trials. However, this needs to be
proven in future prospective studies. Nevertheless, the
data at present are preliminary and verification in a sec-
ond cohort is needed including evaluation in milder
COPD. Furthermore, data should additionally be evalu-
ated in a “real world” COPD study where the criteria of
extreme annual rate of FEV1 is not included.
Conclusion
In conclusion, we demonstrated that extracellular matrix
markers of tissue turnover were predictive of FEV1
change in patients with COPD and suggest that such
markers may be used as prognostic biomarkers and pos-
sibly biomarkers for patient enrichment in clinical trials.
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